The Center for Biosimilars® recaps the top stories for the week of February 10, 2020.
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 10, 2020.
Number 5: The European League Against Rheumatism (EULAR) updates guidelines to address recommendations on the use of disease-modifying antirheumatic drugs and glucocorticoids to treat patients with rheumatoid arthritis.
Number 4: Patents on nearly 20 oncology biologics will expire by 2023, which could lead to more biosimilars in cancer care and lower costs, a review article says.
Number 3: At the Specialty Therapies and Biosimilars Congress, a review of the orphan drug market predicts hefty biosimilar competition, although patent struggles need resolution, according to one speaker.
Number 2: Also at the Congress, the director of pharmacy for Emory Healthcare discusses how they developed a strong in-house specialty pharmacy and cut dependence on outside for-profit specialty pharmacies and managed to strengthen adherence and improve patient outcomes.
Number 1: A review of the 2020 pipeline shows oncology biosimilars are starting to gain some traction in the marketplace.
To read all of these articles and more, visit centerforbiosimilars.com.